Autonomix Medical Clears Nasdaq Hurdle After Reverse Split
AMIX sits 59% above its 52-week low of $4.204 on light trading volume (0.2× avg).
Summary
Nasdaq has confirmed that Autonomix Medical regained compliance with the $1 minimum bid price rule, closing the delisting matter. The reverse stock split completed in late June successfully lifted the share price above the threshold.
Key Events · Legal and Risk Events · AMIX
-
Nasdaq Compliance Regained
On July 9, 2026, Nasdaq confirmed that Autonomix Medical has regained compliance with the $1.00 minimum bid price rule, officially closing the delisting matter.
-
Reverse Split Achieves Goal
The 1-for-21 reverse stock split completed on June 24, 2026 successfully lifted the stock price above $1.00 for the required 10 consecutive business days.
-
Delisting Threat Removed
The Nasdaq deficiency letter received in January 2026 is now resolved, removing the immediate risk of delisting from the Nasdaq Capital Market.
-
Underlying Financial Challenges Remain
Despite regaining compliance, the company still faces a going concern warning and material weaknesses in internal controls as disclosed in its recent 10-K.
Analysis · AMIX · Industrial Applications And Services
The delisting threat that had been hanging over Autonomix Medical since January is now officially resolved. Nasdaq confirmed on July 9, 2026, that the company has regained compliance with the minimum bid price rule. The 1-for-21 reverse split completed on June 24 did its job—the stock held above $1 for 10 consecutive days. For a micro-cap carrying a going concern warning, this removes an immediate existential risk, though the underlying financial challenges remain.
At the time of this filing, AMIX was trading at $6.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $4.20 to $55.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.